{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T21:22:44Z","timestamp":1649107364994},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T00:00:00Z","timestamp":1237420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s12328-009-0065-0","type":"journal-article","created":{"date-parts":[[2009,3,18]],"date-time":"2009-03-18T01:35:51Z","timestamp":1237340151000},"page":"210-213","source":"Crossref","is-referenced-by-count":0,"title":["Successful cessation of lamivudine using interferon in a patient with chronic hepatitis\u00a0B who received prophylactic lamivudine treatment during chemotherapy"],"prefix":"10.1007","volume":"2","author":[{"given":"Kazuhiko","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Katano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Hirooka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,19]]},"reference":[{"key":"65_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1473-3099(02)00315-8","volume":"2","author":"JH Kao","year":"2002","unstructured":"Kao JH, Chen DS. Global control of hepatitis\u00a0B virus infection. Lancet Infect Dis. 2002;2:395\u2013403.","journal-title":"Lancet Infect Dis"},{"key":"65_CR2","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMra031087","volume":"350","author":"D Ganem","year":"2004","unstructured":"Ganem D, Prince AM. Hepatitis\u00a0B virus infection\u2013natural history and clinical consequences. N Engl J Med. 2004;350:1118\u201329.","journal-title":"N Engl J Med"},{"key":"65_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.7326\/0003-4819-96-4-447","volume":"96","author":"JH Hoofnagle","year":"1982","unstructured":"Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, et al. Reactivation of chronic hepatitis\u00a0B virus infection by cancer chemotherapy. Ann Intern Med. 1982;96:447\u20139.","journal-title":"Ann Intern Med"},{"key":"65_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.1999.17.1.394","volume":"7","author":"R Liang","year":"1999","unstructured":"Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis\u00a0B carriers: a review of the problem. J Clin Oncology. 1999;7:394\u20138.","journal-title":"J Clin Oncology"},{"key":"65_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","volume":"62","author":"W Yeo","year":"2000","unstructured":"Yeo W, Chan PKS, Zhong S, Ho WM, Steimberg JL, Tam JS, et al. Frequency of hepatitis\u00a0B virus reactivation in cancer patient undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299\u2013307.","journal-title":"J Med Virol"},{"key":"65_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/gut.51.4.597","volume":"51","author":"SG Lim","year":"2002","unstructured":"Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis\u00a0B reactivation following discontinuation of nucleoside analogues for chronic hepatitis\u00a0B. Gut. 2002;51:597\u20139.","journal-title":"Gut"},{"key":"65_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/hep.21513","volume":"45","author":"AS Lok","year":"2007","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis\u00a0B. Hepatology. 2007;45:507\u201339.","journal-title":"Hepatology"},{"key":"65_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","volume":"136","author":"G Lalazar","year":"2007","unstructured":"Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis\u00a0B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699\u2013712.","journal-title":"Br J Haematol"},{"key":"65_CR9","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","volume":"341","author":"JL Dienstag","year":"1999","unstructured":"Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis\u00a0B in the United States. New Engl J Med. 1999;341:1256\u201363.","journal-title":"N Engl J Med"},{"key":"65_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1053\/gast.2000.8559","volume":"119","author":"YF Liaw","year":"2000","unstructured":"Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis\u00a0B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119:172\u201380.","journal-title":"Gastroenterology"},{"key":"65_CR11","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","volume":"125","author":"AS Lok","year":"2003","unstructured":"Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis\u00a0B. Gastroenterology. 2003;125:1714\u201322.","journal-title":"Gastroenterology"},{"key":"65_CR12","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","volume":"125","author":"GK Lau","year":"2003","unstructured":"Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis\u00a0B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742\u20139.","journal-title":"Gastroenterology"},{"key":"65_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2036.2004.01845.x","volume":"19","author":"VW Wong","year":"2004","unstructured":"Wong VW, Chan HL, Wong ML, Tam JS, Leung NW. Clinical course after stopping lamivudine in chronic hepatitis\u00a0B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther. 2004;19:323\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"65_CR14","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1136\/gut.2005.070763","volume":"54","author":"CK Hui","year":"2005","unstructured":"Hui CK, Cheung WW, Au WY, Lie AK, Zhang HY, Yueng YH, et al. Hepatitis\u00a0B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005;54:1597\u2013603.","journal-title":"Gut"},{"key":"65_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1046\/j.1365-2141.2001.03099.x","volume":"115","author":"G Rossi","year":"2001","unstructured":"Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis\u00a0B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001;115:58\u201362.","journal-title":"Br J Haematol"},{"key":"65_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1182\/blood.V100.2.391","volume":"100","author":"O Shibolet","year":"2002","unstructured":"Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis\u00a0B virus reactivation in hepatitis\u00a0B surface antigen carriers. Blood. 2002;100:391\u20136.","journal-title":"Blood"},{"key":"65_CR17","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1053\/jhep.2002.35068","volume":"36","author":"GK Lau","year":"2002","unstructured":"Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, et al. Preemptive use of lamivudine reduces hepatitis\u00a0B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002;36:702\u20139.","journal-title":"Hepatology"},{"key":"65_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1046\/j.1365-2893.2003.00479.x","volume":"11","author":"R Idilman","year":"2004","unstructured":"Idilman R, Arat M, Soydan E, T\u00f6r\u00fcner M, Soykan I, Akbulut H, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis\u00a0B virus reactivation in hepatitis\u00a0B virus carriers with malignancies. J Viral Hepat. 2004;11:141\u20137.","journal-title":"J Viral Hepat"},{"key":"65_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","volume":"131","author":"CK Hui","year":"2006","unstructured":"Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis\u00a0B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59\u201368.","journal-title":"Gastroenterology"},{"key":"65_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hep.22213","volume":"48","author":"CK Hui","year":"2008","unstructured":"Hui CK, Cheung WW, Leung KW, Cheng VC, Tang BS, Li IW, et al. Retracted: outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen. Hepatology. 2008;48:1\u201310.","journal-title":"Hepatology"},{"key":"65_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1872-034X.2007.00094.x","volume":"8","author":"A Matsumoto","year":"2007","unstructured":"Matsumoto A, Tanaka E, Minami M, Okanoue T, Yatsuhashi H, Nagaoka S, et al. Low serum level of hepatitis\u00a0B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatol Res. 2007;8:661\u20136.","journal-title":"Hepatol Res"},{"key":"65_CR22","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"352","author":"GK Lau","year":"2005","unstructured":"Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis\u00a0B. N Engl J Med. 2005;352:2682\u201395.","journal-title":"N Engl J Med"},{"key":"65_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1053\/jhep.2001.26819","volume":"34","author":"L Serfaty","year":"2001","unstructured":"Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouill\u00e8res O, Carbonell N, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis\u00a0B not responding to interferon alone: results of a pilot study. Hepatology. 2001;34:573\u20137.","journal-title":"Hepatology"},{"key":"65_CR24","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1111\/j.1572-0241.2005.00247.x","volume":"100","author":"SK Sarin","year":"2005","unstructured":"Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis\u00a0B patients. Am J Gastroenterol. 2005;100:2463\u201371.","journal-title":"Am J Gastroenterol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-009-0065-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-009-0065-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-009-0065-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-009-0065-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T07:56:13Z","timestamp":1559462173000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-009-0065-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,19]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["65"],"URL":"https:\/\/doi.org\/10.1007\/s12328-009-0065-0","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,19]]}}}